Mirae Asset Global Investments Co. Ltd. Purchases 3,952 Shares of Surgery Partners, Inc. (NASDAQ:SGRY)

Mirae Asset Global Investments Co. Ltd. grew its position in Surgery Partners, Inc. (NASDAQ:SGRY) by 13.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 34,139 shares of the company’s stock after purchasing an additional 3,952 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Surgery Partners were worth $1,092,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. SG Americas Securities LLC acquired a new position in Surgery Partners during the 3rd quarter worth approximately $1,307,000. Raymond James & Associates boosted its holdings in Surgery Partners by 1.2% during the third quarter. Raymond James & Associates now owns 61,188 shares of the company’s stock worth $1,790,000 after purchasing an additional 736 shares during the last quarter. Redwood Investments LLC grew its position in Surgery Partners by 218.7% in the third quarter. Redwood Investments LLC now owns 346,788 shares of the company’s stock valued at $10,144,000 after purchasing an additional 237,970 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Surgery Partners by 6.3% in the 3rd quarter. Bank of New York Mellon Corp now owns 317,983 shares of the company’s stock valued at $9,301,000 after buying an additional 18,900 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Surgery Partners by 15.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,506 shares of the company’s stock worth $307,000 after buying an additional 1,387 shares in the last quarter.

Insider Buying and Selling

In related news, CFO David T. Doherty sold 1,020 shares of the firm’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $34.93, for a total transaction of $35,628.60. Following the completion of the transaction, the chief financial officer now directly owns 74,209 shares of the company’s stock, valued at approximately $2,592,120.37. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, CFO David T. Doherty sold 1,020 shares of the stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $34.93, for a total value of $35,628.60. Following the completion of the sale, the chief financial officer now owns 74,209 shares of the company’s stock, valued at $2,592,120.37. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Bradley R. Owens sold 1,040 shares of Surgery Partners stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $35.22, for a total value of $36,628.80. Following the completion of the transaction, the insider now directly owns 73,149 shares in the company, valued at $2,576,307.78. The disclosure for this sale can be found here. Insiders have sold a total of 18,774 shares of company stock valued at $608,352 over the last 90 days. 2.60% of the stock is owned by insiders.

Surgery Partners Stock Up 0.9 %

Shares of SGRY opened at $24.04 on Tuesday. The stock has a market capitalization of $3.04 billion, a price-to-earnings ratio of -240.40, a PEG ratio of 2.18 and a beta of 2.71. Surgery Partners, Inc. has a 52 week low of $22.05 and a 52 week high of $45.79. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.57 and a current ratio of 1.71. The stock has a fifty day moving average of $29.20 and a 200-day moving average of $29.84.

Surgery Partners (NASDAQ:SGRY) last issued its quarterly earnings data on Monday, February 26th. The company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. Surgery Partners had a negative net margin of 0.43% and a positive return on equity of 3.65%. The business had revenue of $735.40 million during the quarter, compared to analyst estimates of $741.93 million. During the same quarter last year, the business earned $0.22 EPS. The firm’s quarterly revenue was up 4.0% on a year-over-year basis. As a group, sell-side analysts anticipate that Surgery Partners, Inc. will post 0.78 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Barclays assumed coverage on Surgery Partners in a research report on Wednesday, March 6th. They issued an “equal weight” rating and a $35.00 target price on the stock. Royal Bank of Canada reiterated an “outperform” rating and set a $49.00 price objective on shares of Surgery Partners in a research note on Thursday, February 29th. Citigroup lowered their target price on shares of Surgery Partners from $43.00 to $42.00 and set a “buy” rating on the stock in a report on Tuesday, February 27th. StockNews.com upgraded shares of Surgery Partners from a “sell” rating to a “hold” rating in a research note on Thursday, March 21st. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $43.00 price objective on shares of Surgery Partners in a research note on Wednesday, April 10th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, Surgery Partners has a consensus rating of “Moderate Buy” and a consensus target price of $43.63.

About Surgery Partners

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.